Evidence map›Paper›PMID 40423890›Full record

ArticleJournal of bioenergetics and biomembranes2025

NSUN2 contributes to the RB malignant progression and Glycolysis by mediating the m5C methylation modification of HKDC1.

Jing Guan, Lili Lu, Yuantong Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bioenergetics and biomembranes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jing Guan *Department of Ophthalmology, The First People's Hospital of Lanzhou City, No.1 Wujiayuan West Street, Qilihe District, Lanzhou City, Gansu Province, China.
Lili Lu *Department of Ophthalmology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise City, Guangxi, China.
Yuantong JiangDepartment of Ophthalmology, The First People's Hospital of Lanzhou City, No.1 Wujiayuan West Street, Qilihe District, Lanzhou City, Gansu Province, China. jyt198365@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoblastoma (RB) is a malignant neoplasm originating from photoreceptor precursor cells that is common in children under 3 years of age. NOP2/Sun RNA methyltransferase family member 2 (NSUN2) is a major methyltransferase that catalyzes mammalian mRNA 5-methylcytosine (m5C) modification and has been implicated in a variety of diseases, but its mechanism in RB is still incomplete. NSUN2 was up-regulated in RB and was associated with the poor survival of patients. Silencing NSUN2 blocked the malignant behaviors of RB cells. In Y79 cells, the differentially expressed genes (DEGs) after knocking down NSUN2 were mainly concentrated in the glycolytic pathway from the GSE214685 dataset, and NSUN2 down-regulation restrained the glycolysis of RB cells. What's more, the m5C modification and mRNA stability of hexokinase domain component 1 (HKDC1) were mediated by NSUN2 and Y-box binding protein 1 (YBX1). Mechanically, NSUN2 promoted RB malignant behaviors and glycolysis in vitro via HKDC1 and accelerated tumor growth in vivo. Our study put forward a new mechanism to regulate RB progression, namely, NSUN2 and YBX1 synergistically promote malignant progression and glycolysis of RB by mediating HKDC1 m5C modification.

Indexed as

GlycolysisHexokinaseMethyltransferasesRetinoblastomaAnimalsCell Line, TumorDisease ProgressionHumansMethylationMiceHexokinaseMethyltransferasesNSUN2 protein, human5-methylcytosineGlycolysisHexokinase domain component 1NOP2/Sun RNA methyltransferase family member 2Retinoblastoma

Identifiers

PMID40423890

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.